5 Topic Commentaries

The Scalability Challenge in MSC Therapies

• 

  Abba Zubair, M.D., Ph.D.

  Transfusion Medicine and Cell Therapy

  •

  Mayo Clinic

  This may make treatments possible in cases where the patient’s own cells are not viable as therapy. In addition, because the cells can be produced in days instead of months, it may also make treatments available on short notice when they’re needed for acute care.

  Source
• 

  Atta Behfar, M.D., Ph.D.

  Cardiology and Regenerative Medicine

  •

  Mayo Clinic

  Use of an automated cell manufacturing platform not only advances Mayo’s existing cell therapy capabilities, but also opens the door toward establishment of engineered cell-therapy platforms, transforming our ability to pursue targeted biologics-based approaches across Mayo Clinic in Arizona, Florida and Minnesota. The FDA allowance of this latest generation cell manufacturing platform not only allows Mayo to continue its quest to develop treatments in areas of unmet patient needs, but positions us at the forefront of regenerative innovation.

  Source
• 

  Guojun Bu, Ph.D.

  Neurology and Regenerative Medicine

  •

  Mayo Clinic

  The new platform represents a giant leap in regenerative medicine, in which stem cells currently are being investigated as treatments for wide-ranging medical conditions.

  Source
• 

  Linzhao Cheng, Ph.D.

  Stem Cell Biology and Oncology

  •

  Johns Hopkins Medicine

  We wanted to show other scientists working on such potential therapies that human iPSCs can efficiently produce highly purified extracellular vesicles that could, one day, be used to treat aging-related diseases.

  Source
• 

  Jongyoon Han, Ph.D.

  Biological Engineering and Biomanufacturing

  •

  Massachusetts Institute of Technology

  The findings support µMRR‑based iron monitoring as an effective quality control strategy for MSC-based therapy manufacturing, paving the way for more consistent and clinically viable regenerative medicine for cartilage regeneration.

  Source